Year: 2021

28. februar 2022               Bestyrelsen behandler Årsrapport 2021, som efterfølgende offentliggøres. 21. marts 2022                  Ordinær generalforsamling. 22. august 2022                Bestyrelsen behandler Halvårsrapport 2022, som efterfølgende offentliggøres. Spørgsmål kan rettes til undertegnede på telefon 3814 6600. Med venlig hilsen Niels Erik EberhardDirektør

25. februar 2022               Bestyrelsen behandler Årsrapport 2021, som efterfølgende offentliggøres. 22. marts 2022                 Ordinær generalforsamling. 16. august 2022                Bestyrelsen behandler Halvårsrapport 2022, som efterfølgende offentliggøres.Spørgsmål kan rettes til undertegnede på telefon 3814 6600.Med venlig hilsen Niels Erik EberhardDirektør

21. februar 2022               Bestyrelsen behandler Årsrapport 2021, som efterfølgende offentliggøres. 7. marts 2022                   Ordinær generalforsamling. 15. august 2022                Bestyrelsen behandler Halvårsrapport 2022, som efterfølgende offentliggøres.Spørgsmål kan rettes til undertegnede på telefon 3814 6600.Med venlig hilsen Niels Erik Eberhard Direktør

2. marts 2022                    Bestyrelsen behandler Årsrapport 2021, som efterfølgende offentliggøres. 16. marts 2022                  Ordinær generalforsamling. 17. august 2022                Bestyrelsen behandler Halvårsrapport 2022, som efterfølgende offentliggøres.Spørgsmål kan rettes til undertegnede på telefon 3814 6600.Med venlig hilsen Niels Erik EberhardDirektør

1. marts 2022                   Bestyrelsen behandler Årsrapport 2021, som efterfølgende offentliggøres. 15. marts 2022                 Ordinær generalforsamling. 23. august 2022                Bestyrelsen behandler Halvårsrapport 2022, som efterfølgende offentliggøres.Spørgsmål kan rettes til undertegnede på telefon 3814 6600. Med venlig hilsen Niels Erik EberhardDirektør

9. marts 2022                    Bestyrelsen behandler Årsrapport 2021, som efterfølgende offentliggøres. 30. marts 2022                  Ordinær generalforsamling. 24. august 2022                Bestyrelsen behandler Halvårsrapport 2022, som efterfølgende offentliggøres. Spørgsmål kan rettes til undertegnede på telefon 3814 6600. Med venlig hilsen Niels Erik EberhardDirektør

Corporate CommunicationsADVERTISEMENT. This announcement is an advertisement for the purposes of Regulation (EU) 2017/1129, as amended (the “Prospectus Regulation”) relating to the intention of Iveco Group N.V. (the “Company”) to proceed with the proposed first admission to listing and trading of all of the common shares of the Company on the regulated market of Euronext Milan (the “Admission”). This announcement does not constitute or form part of a prospectus within the meaning of the Prospectus Regulation and has not been reviewed nor approved by any regulatory or supervisory authority in any jurisdiction, including any member state of the European Economic Area (each, an “EEA Member”), the United Kingdom and the United States. This announcement is for information purposes only and is not intended to constitute, and should not...

Cavotec has won two key orders for its motorised cable reel electrification systems for container cranes at major ports in China and the US from leading crane manufacturer ZPMC. The orders highlight how Cavotec manufactures mission-critical systems that improve safety, maximize efficiency, and minimize environmental impact. The total value of the two orders amounts to more than EUR 1.3M. For the first order, Cavotec will supply motorised cable reel systems for electrification of rail-mounted gantry cranes for a container yard at the Port of Taicang in China.  The second order is a repeat order for motorised cable reel systems for gantry and spreader systems on ship-to-shore container cranes at the Port of Los Angeles.  These orders demonstrate how Cavotec’s motorised cable reel systems reduce the environmental impact of container handling...

There are no currently approved therapies impacting disease progression for the up to 8 million people suffering from geographic atrophy (GA)1,2Acquisition will add GT005 to the Novartis portfolio, an investigational, one-time gene therapy currently in Phase 2 for the treatment of people living with GAPotential to be the first therapy with sustained efficacy for a broad GA patient population Acquisition complements Novartis established expertise in retinal diseases and gene therapy and further builds position in ophthalmology gene therapy and optogenetics following acquisitions of Vedere Bio and Arctos MedicalBasel, December 22, 2021 — Novartis announced today that it entered into a definitive agreement to acquire all of the outstanding share capital of the UK-based ocular gene therapy company Gyroscope Therapeutics. Geographic...

AB “Ignitis grupė” financial calendar 2022 AB “Ignitis grupė” (hereinafter – the Group) announces its reporting dates for 2022, including the dates of the General Meetings of Shareholders:28 February 2022: (i) Interim report for the twelve months of 2021(ii) Annual audited financial statements for 2021, annual report for 2021 verified by auditors and proposed allocation of profit (loss)29 March 2022: Ordinary General Meeting of Shareholders11 April 2022: Expected Ex-Dividend Date (for ordinary registered shares)12 April 2022: Expected Record Date for dividend payment (for ordinary registered shares)19 May 2022: Interim report for the first quarter of 202223 August 2022: Interim report for the first half of 202229 September 2022: Extraordinary General Meeting of Shareholders (regarding the potential allocation of dividends...